Last reviewed · How we verify
Rauwolfia alkaloids
Rauwolfia alkaloids decrease sympathetic nervous system activity by inhibiting the release of norepinephrine.
Rauwolfia alkaloids decrease sympathetic nervous system activity by inhibiting the release of norepinephrine. Used for Hypertension.
At a glance
| Generic name | Rauwolfia alkaloids |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Antihypertensive |
| Target | Dopamine beta-hydroxylase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
This is achieved through the inhibition of the enzyme dopamine beta-hydroxylase, which is responsible for converting dopamine to norepinephrine. By reducing norepinephrine levels, rauwolfia alkaloids lead to decreased heart rate, blood pressure, and cardiac workload.
Approved indications
- Hypertension
Common side effects
- Drowsiness
- Dry mouth
- Postural hypotension
Key clinical trials
- Treatment of Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |